Rongen

Heinz Rongen, Dueren DE

Patent application number	Description	Published
20090069662	Device for Measuring Biomedical Data of a Test Subject and Method for Stimulating the Test Subject Using Data Processed in Real Time - Provided is a device for measuring biomedical data from a testee, with a recording system for taking the data and a first hardware component for displaying the data. A device for electrical separation of the data is arranged in a connector line for transmitting the data from the recording system to the first hardware component for displaying the data. At least a duplication of the data for data processing purposes is thus guaranteed. The data processed in said manner are used for a method for real-time stimulation of a testee.	03-12-2009
20100047751	PHANTOM - A phantom comprises at least one first means for generating at least one dipole and at least one second means for actuating the first means in a non-electrical manner.	02-25-2010

Peter H. Rongen, Dx Amersfoort NL

Patent application number	Description	Published
20100169066	General Framework to Predict Parametric Costs - A method of simulating an information technology (IT) system to produce parametric data includes translating specifications of the IT system from a first modeling language to a second modeling language; incorporating component constraints into the translated specifications; simulating operation of the IT system based on the translated specifications and the component constraints; and generating a report of parametric data based on the simulation.	07-01-2010

Rene Theodora Hubertus Rongen, Nijmegen NL

Patent application number	Description	Published
20120211845	Integrated Circuit with Sensor and Method of Manufacturing Such an Integrated Circuit - Disclosed is an integrated circuit comprising a substrate (	08-23-2012

Roelof Rongen, Califon, NJ US

Patent application number	Description	Published
20130259852	LYSOZYME GEL FORMULATIONS - The present invention relates to formulations of gelled lysozyme achieved by the addition of water to a lysozyme suspension in a solvent, such as an alcohol, with retention of enzymatic activity. It was surprisingly discovered that lysozyme itself is a gelling substance (self-gel) and, therefore, it can be advantageously formulated into topical compositions without the addition of other gelling substances such as cellulose, starch or other polysaccharides. The activity of the lysozyme is enhanced as compared to other formulations of comprising lysozyme. The formulations contained in the present invention are useful in methods in the fields of therapeutics, disinfectants, sanitizers, personal hygiene, and cosmetics for human and veterinary use.	10-03-2013
20140107199	OMEGA-3 PENTAENOIC ACID COMPOSITIONS AND METHODS OF USE - Orally administrable composition comprising fatty acids comprising omega-3-fatty acids, salts or derivatives thereof are provided. These compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases/conditions or risk factors therefore.	04-17-2014
20140194512	COMPOSITIONS COMPRISING DOCOSAPENTAENOIC ACID AND METHODS OF USE - Orally administrable composition comprising fatty acids comprising docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA). The compositions can be used for the treatment or prophylaxis of a variety of conditions, including liver-related conditions.	07-10-2014

Roelof M. Rongen, Caliton, NJ US

Patent application number	Description	Published
20140080889	Statin and Omega-3 Fatty Acids for Lipid Therapy - A method and composition for lipid therapy. In some embodiments, the method comprises providing a subject group having a baseline triglyceride level of 200 to 499 mg/dl and being at or near its low-density lipoprotein cholesterol (LDL-C) level goal, and reducing the triglyceride level and the non-high-density lipoprotein cholesterol (non-HDL-C) level of the subject group as compared to treatment with a 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) inhibitor alone, by administering to the subject group an effective amount of an HMG CoA inhibitor and a composition comprising omega-3 fatty acids.	03-20-2014

Roelof M.l. Rongen, Califon, NJ US

Patent application number	Description	Published
20100010026	STATIN AND OMEGA-3 FATTY ACIDS FOR REDUCTION OF APO-B LEVELS - Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.	01-14-2010
20110251275	OMEGA-3 FATTY ACIDS FOR REDUCTION OF LP-PLA2 LEVELS - Methods are provided for utilizing omega-3 fatty acids, or a combination of a dyslipidemic agent and omega-3 fatty acids, for the reduction of lipoprotein-associated phospholipase A	10-13-2011

Roelof M. L. Rongen, Tarpon Springs, FL US

Patent application number	Description	Published
20090239927	Statin and Omega-3 Fatty Acids For Lipid Therapy - A method of lipid therapy, comprising providing a subject group having a baseline triglyceride level of 200 to 499 mg/dl and being at or near its low-density lipoprotein cholesterol (LDL-C) level goal, and reducing the triglyceride level and the non-high-density lipoprotein cholesterol (non-HDL-C) level of the subject group as compared to treatment with a 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) inhibitor alone, by administering to the subject group an effective amount of an HMG CoA inhibitor and a composition comprising omega-3 fatty acids.	09-24-2009

Roelof M. L. Rongen, Califon, NJ US

Patent application number	Description	Published
20090182022	Treatment of Fatty Liver - Methods and compositions comprising peroxisomal and/or mitochondrial beta oxidation stimulating agents to reverse or resolve, slow the progression of, treat or prevent the development of fatty liver and conditions stemming from fatty liver, such as NASH, liver inflammation, cirrhosis and liver failure. An active agent that by itself is associated with an increased risk of fatty liver development and conditions stemming from fatty liver, such as NASH, liver inflammation, cirrhosis and liver failure, may be administered in combination with peroxisomal and/or mitochondrial beta oxidation stimulating agents. A combination regimen involving such agents, as simultaneous or concomitant therapy, or as a fixed dosage form, is also provided.	07-16-2009
20110092563	STATIN AND OMEGA-3 FATTY ACIDS FOR LIPID THERAPY - A method of lipid therapy, comprising providing a subject group having a baseline triglyceride level of 200 to 499 mg/dl and being at or near its low-density lipoprotein cholesterol (LDL-C) level goal, and reducing the triglyceride level and the non-high-density lipoprotein cholesterol (non-HDL-C) level of the subject group as compared to treatment with a 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) inhibitor alone, by administering to the subject group an effective amount of an HMG CoA inhibitor and a composition comprising omega-3 fatty acids.	04-21-2011

Roelof M. L. Rongen, Caliton, NJ US

Patent application number	Description	Published
20090012167	Omega-3 Fatty Acids and Dyslipidemic Agent for Lipid Therapy - A method and composition for blood lipid therapy by administering to the subject an effective amount of a dyslipidemic agent and omega-3 fatty acids. The method utilizes a single administration or a unit dosage of a combination of dyslipidemic agent and omega-3 fatty acids for the treatment of patients with hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, coronary heart disease (CHD), vascular disease, artherosclerotic disease and related conditions, and the prevention or reduction of cardiovascular and vascular events.	01-08-2009